Insomnia

• Cannabis, Cannabinoids, and Sleep: a Review of the Literature
  – View Article

Malignant Disease – Pain

• Study – Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases
  – M Darkovska-Serafimovska 2018 (1:1 Sativex) View Article

Chronic Pain

• Systematic reviews on therapeutic efficacy and safety of Cannabis (including extracts and tinctures) for patients with multiple sclerosis, chronic neuropathic pain, dementia and Tourette syndrome, HIV/AIDS, and cancer receiving chemotherapy
  – L Amato 2017 (1:1 Sativex) View Article

Neuropathic Pain – MS

• A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis
  – RM Langford 2013 (1:1 Sativex) View Article
• Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
  – D Rog 2007 (1:1 Sativex) View Article
• Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
  – D Rog 2005 (1:1 Sativex) View Article

Non-cardiac Chest Pain

• Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial
  – Z Malik 2016 (THC – Dronabinol) View Article

Chronic Spinal Cord Injury

• Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons
  – K Ethans 2015 (THC – Dronabinol) View Article

Pancreatitis – Abdominal Pain

• Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain
  – H Van Goor 2014 (THC – Namisol) View Article

Neuropathic Pain – MS

• Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis
  – S Schimrgk 2010 (THC – Dronabinol) View Article

Neurological Pain

• A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin
  – W Notcutt 2002 (THC – Marinol) View Article

Cancer – Pain

• Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain
  – A Lichtman 2018 (1:1 Sativex) View Article
• Medical Marijuana Use in Oncology A Review
  – G Wilkie 2016 (1:1 Sativex) View Article
• Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract & THC Extract in Patients w/Intractable Cancer-Related Pain
  – J Johnson 2010 (1:1 Oro-mucosal spray) View Article

Adv Cancer – Pain

• An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics
  – J Johnson 2013 (1:1 Sativex) View Article

Opiod-Refractory Cancer Pain

• Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial
  – RK Portenoy 2012 (1:1 Sativex) View Article

Cancer – Childhood Chemo Nausea Vomiting

• Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood
  – R Phillips 2016 (THC – Cannabis) View Article 

Chemotherapy Induced Nausea

• Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics.
  – M May 2016 (THC-Dronabinol) View Article

Cancer – Nausea and Vomiting

• Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
  – LA Smith 2015 (THC-Cannabis Exacts) View Article
• Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system
  – KA Sharkey 2014 (THC-Dronabinol, 1:1 Sativex) View Article
• Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting
  – E Meiri 2007 (THC-Dronabinol) View Article

HIV/AIDS – Morbidity and Mortality

• The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS.
  – EE Lutge 2013 (THC-Cannabis) View Article

Lung Cancer – Anorexia

• The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial
  – JG Turcott 2018 (THC-Nabilone) View Article

Anorexia and Weight Loss

• Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer
  – M Badowski 2018 (THC-Dronabinol) View Article 

HIV-Wasting Syndrome

• A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
  – G Galetto 2008 (THC-Dronabinol Megestrol) View Article

Cancer – Anorexia

• Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study
  – A Jatoi 2002 (THC-Dronabinol) View Article

Refer to Epilepsy Category

Epilepsy – Children

• Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study
  – M Hausman-Kedem 2018 (20:1) View Article

Epilepsy

• Epilepsy and Cannabis: A Literature Review
  – S Zaheer 2018 (CBD:THC and CBD) View Article
• Cannabinoids and Epilepsy
  – EC Rosenberg 2015 (CBD) View Article
• Epilepsy Cannabinoids for epilepsy
  – D Gloss 2014 (CBD) View Article

Epilepsy – Pediatric

• CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience
  – M Tzadok 2016 (20:1) View Article

MS

• Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to
  multiple sclerosis
  – U Zetti 2016 (1:1 Oro-mucosal spray) View Article
• Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice
  – P Vermersch 2016 (1:1 Sativex) View Article
• Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
  – L Leocani 2015 (1:1 Sativex) View Article
• Advances in the management of multiple sclerosis spasticity: recent clinical trials.
  – O Fernandez 2014 (1:1 Sativex) View Article
• A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
  – C Collin 2010 (1:1 Sativex) View Article
• Randomized controlled trial of cannabis based medicine in spasticity caused by multiple sclerosis
  – C Collin 2007 (1:1 Oro- mucosal spray) View Article
• Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
  – D Wade 2004 (1:1 Sativex) View Article

MS-Neurologic Disorders

• Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders
  – B Koppel 2014 (1:1 Sativex) View Article

Spasticity

• Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol
  – D Boggs 2018 (1:1 Sativex) View Article

Chronic Spinal Cord Injury

• Delta-9-tetrahydrocannabinol-cannabidiol in the treatment of spasticity in chronic spinal cord injury: a clinical experience
  – C Grao-Castellote 2017 (1:1 Sativex) View Article

Spasticity – MS Induced

• Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis
  – U Zetti 2016 (1:1 Oro-mucosal spray) View Article
• Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice
  – P Vermersch 2016 (1:1 Sativex) View Article
• Sativex® and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
  – L Leocani 2015 (1:1 Sativex) View Article
• Advances in the management of multiple sclerosis spasticity: recent clinical trials.
  – O Fernandez 2014 (1:1 Sativex) View Article
• A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
  – C Collin 2010 (1:1 Sativex) View Article
• Randomized controlled trial of cannabis based medicine in spasticity caused by multiple sclerosis
  – C Collin 2007 (1:1 Oro-mucosal CBM) View Article
• Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
  – D Wade 2004 (1:1 Sativex) View Article

Chronic Spinal Cord Injury

• Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons
  – K Ethans 2015 (THC-Dronabinol) View Article

Spasms – ALS

• Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS)
  – M Weber 2009 (THC-Dronabinol) View Article

Refer to Spasticity Category

MS, Autism, Parkinsons, Alzheimers, Tourette’s, Huntington’s, Epilepsy

• Neurological Disorders in Medical Use of Cannabis: An Update
  – R Solimini 2017 (THC, CBD, plant) View Article

Parkinsons

• The Therapeutic Potential of Cannabinoids for Movement Disorders
  – B Kluger 2015 (THC-Nabilone) View Article
• Cannabis for dyskinesia in Parkinson disease A randomized double-blind crossover study
  – CB Carroll 2004 (Extract-Oral Cannabis) View Article
• Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study
  – KA Sierdzan 2001 (THC-Nabilone) View Article

PD-Neurologic Disorders

• Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders
  – B Koppel 2014 (THC, plant) View Article

Glaucoma

• Marijuana and Glaucoma
  – T Graul 2018 (THC) View Article

Retinal Hemodynamics

• Dronabinol and retinal hemodynamics in humans
  – N Plange 2007 (THC-Dronabinol) View Article

Interocular Pressure

• Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. [CBD shown to cause adverse events.]
  – I Tomida 2006 (Sublingual THC & CBD) View Article

PTSD

• Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention
  – M Zer-Aviv 2016 (THC-Nabilone) View Article
• Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder
  – P Roitman 2014 (Oral THC) View Article

PTSD – Nightmares

• The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study
  – R Jetly 2015 (THC-Nabilone) View Article

PTSD – Nightmares, Insomnia, Chronic Pain

• Use of a Synthetic Cannabinoid in a Correctional Population for Posttraumatic Stress Disorder–Related Insomnia and Nightmares, Chronic Pain, Harm Reduction, and Other Indications
  – C Cameron 2014 (THC-Nabilone) View Article

Autism

• Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasibility Study
  – A Aran 2018 (20:1) View Article
• Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities
  – D Barchel 2018 (20:1) View Article

Crohns

• Cannabis finds its way into treatment of Crohn’s disease
  – R Schicho 2014 (THC, plant) View Article
• Side effects, health risks, and a short duration of action limit the usefulness of this drug
  – T Naftali 2013 (THC) View Article

Malignant Disease – Pain

• Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases
  – M Darkovska-Serafimovska 2018 (1:1 Sativex) View Article